Trial Profile
Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC).
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Mitoxantrone (Primary) ; Prednisone (Primary) ; Sorafenib (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 03 May 2010 Planned end date changed from Jul 2008 to Jan 2009 as reported by ClinicalTrials.gov.
- 03 May 2010 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 15 Jul 2008 Status changed in progress to terminated as reported by ClinicalTrials.gov.